TVA Medical, Inc. (TVA), an Austin, Texas-based medical device company developing minimally invasive therapies for End-Stage Renal Disease (ESRD), has raised $2.6m Series A investment from early-stage life science venture capital firm Santé Ventures.
Santé formed the new company in partnership with TVA Founder, William (Billy) Cohn, MD, a cardiovascular surgeon and the Director of Minimally Invasive Surgical Technology at the Texas Heart Institute (THI) at St. Luke’s Episcopal Hospital in Houston, Texas.
Cohn has also joined Santé Ventures as a Venture Partner.
The company will use the funding to complete product development and conduct human clinical trials.
In conjunction with the Series A financing, Adam Berman will join TVA as CEO.
Santé’s Cunningham and Kevin Lalande will serve on TVA’s board of directors.